Women's health and obstetrics: clinical-trial pipeline
24,823 women's health and obstetrics trials are in ClinicalTrials.gov and the EU CTIS portal; 5,655 are not yet finished and 391 of those are in phase 2/3 or 3. Source: Arcadium Data, data as of .
Open trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 3,953 |
| Phase 2 | 555 |
| Phase 3 | 339 |
| Phase 1 | 259 |
| Phase 4 | 249 |
| Phase 1/2 | 185 |
| Early phase 1 | 63 |
| Phase 2/3 | 52 |
Sponsors with the most open trials
Recently changed open trials
| Registry id | Title | Sponsor | Phase | Status | Countries |
|---|---|---|---|---|---|
| NCT04644289 | WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC | AGO Research GmbH | Phase 2 | Recruiting | Germany |
| NCT01844986 | Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum B… | AstraZeneca | Phase 3 | Active, not recruiting | Australia, Brazil, Canada, China +11 |
| NCT06833788 | Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum Depression | Assistance Publique - Hôpitaux de Paris | Phase 4 | Recruiting | France |
| NCT04579380 | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 | Active, not recruiting | Belgium, Germany, Spain, United Kingdom +4 |
| NCT03602859 | A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-base… | Tesaro, Inc. | Phase 3 | Active, not recruiting | Belgium, Belarus, Canada, Czechia +15 |
| NCT05410275 | Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients | University Hospital, Tours | Phase 3 | Recruiting | France |
| NCT04752826 | BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D… | BioInvent International AB | Phase 1/2 | Recruiting | Denmark, Spain, United Kingdom, Hungary +3 |
| 2023-510280-35-00 | Effective strategy of withdrawal of pharmacological treatment of urinary incontinence in children (StayDry) | Region Midtjylland | Phase 4 | Active, not recruiting | Denmark |
| 2023-510187-13-00 | Efficacy of solifenacin, mirabegron and combination therapy in children with overactive bladder and daytime u… | Region Midtjylland | Phase 3 | Recruiting | Denmark |
| NCT06195163 | TRAP Study: Testosterone for Androgen Receptor Polymorphism | Instituto Bernabeu | Phase 4 | Not yet recruiting | Spain |
| NCT05899010 | MIcronized PROgesterone in Frozen Embryo Transfer Cycles | Santiago Dexeus Font Fundacio Privada | Phase 3 | Recruiting | Spain |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | PMV Pharmaceuticals, Inc | Phase 1/2 | Recruiting | Australia, Germany, Spain, France +5 |
| NCT04188548 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer | Eli Lilly and Company | Phase 1 | Active, not recruiting | Australia, Belgium, Spain, France +4 |
| NCT03772028 | Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | The Netherlands Cancer Institute | Phase 3 | Active, not recruiting | Germany, Denmark, France, Ireland +4 |
| NCT04232917 | Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections. | Labo'Life | Phase 4 | Recruiting | Belgium, Romania |
| NCT06497959 | Study of Placental Vascularization Using Contrast Ultrasound | Central Hospital, Nancy, France | Phase 3 | Recruiting | France |
| NCT05983432 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other So… | SystImmune Inc. | Phase 1 | Recruiting | Spain, France, Italy, Japan +1 |
| NCT05277051 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | GlaxoSmithKline | Phase 1 | Active, not recruiting | Australia, Canada, China, Spain +5 |
| 2024-510701-29-00 | Randomized Clinical Trial of the use of Propofol as a sedative agent versus spinal analgesia with bupivacaine… | Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia | Phase 4 | Recruiting | Spain |
| 2023-507289-14-00 | A PHASE II, RANDOMIZED, DOUBLE BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AMY109 IN WOMEN WITH ENDOME… | Chugai Pharmaceutical Co. Ltd. | Phase 2 | Active, not recruiting | Czechia, Poland, Romania |
All areas: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Women's health and obstetrics clinical trials: 5,655 open, 391 in phase 3", https://arcadiumdata.io/clinical-trials/area/womens-health/, data as of 2026-10-25.